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Background. Hemolytic uremic syndrome (HUS) is caused by enterohemorrhagic Escherichia coli (EHEC) which possess genes
encoding Shiga toxin (stx), the major virulence factor, and adhesin intimin (eae). However, the frequency of stx-negative/eae-
positive E. coli in stools of HUS patients and the clinical significance of such strains are unknown. Methodology/Principal
Findings. Between 1996 and 2006, we sought stx-negative/eae-positive E. coli in stools of HUS patients using colony blot
hybridization with the eae probe and compared the isolates to EHEC causing HUS. stx-negative/eae-positive E. coli were
isolated as the only pathogens from stools of 43 (5.5%) of 787 HUS patients; additional 440 (55.9%) patients excreted EHEC.
The majority (90.7%) of the stx-negative/eae-positive isolates belonged to serotypes O26:H11/NM (nonmotile), O103:H2/NM,
O145:H28/NM, and O157:H7/NM, which were also the most frequent serotypes identified among EHEC. The stx-negative
isolates shared non-stx virulence and fitness genes with EHEC of the corresponding serotypes and clustered with them into the
same clonal complexes in multilocus sequence typing, demonstrating their close relatedness to EHEC. Conclusions/
Significance. At the time of microbiological analysis, ,5% of HUS patients shed no longer the causative EHEC, but do excrete
stx-negative derivatives of EHEC that lost stx during infection. In such patients, the EHEC etiology of HUS is missed using
current methods detecting solely stx or Shiga toxin; this can hamper epidemiological investigations and lead to inappropriate
clinical management. While maintaining the paradigm that HUS is triggered by Shiga toxin, our data demonstrate the
necessity of considering genetic changes of the pathogen during infection to adapt appropriately diagnostic strategies.
Citation: Bielaszewska M, Ko ¨ck R, Friedrich AW, von Eiff C, Zimmerhackl LB, et al (2007) Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to
Change the Diagnostic Paradigm?. PLoS ONE 2(10): e1024. doi:10.1371/journal.pone.0001024
INTRODUCTION
Hemolytic uremic syndrome (HUS) consists of microangiopathic
hemolytic anemia, thrombocytopenia, and renal insufficiency [1].
It usually develops after prodromal diarrhea, which is often bloody
[1,2]. HUS is a leading cause of acute renal failure in children [3]
and the mortality during the acute phase reported in recent studies
was ,2% [4–6]; many survivors suffer from renal or non-renal
sequelae [1,3].
The major etiological agents of HUS are enterohemorrhagic
Escherichia coli (EHEC) strains belonging to serotype O157:H7 and
several other serotypes, including O26:H11/NM (nonmotile),
O103:H2/NM, O111:H8/NM, O145:H28/NM, and O157:NM
[1,2,4–11]. The cardinal virulence traits of EHEC are Shiga toxins
(Stx) [12], which cause microvascular endothelial injury in kidneys
and other organs resulting in the characteristic thrombotic
microangiopathy that forms the histopathological basis of HUS
[1,13]. Stx production is mediated by lysogenic conversion of
EHEC with stx-harboring prophages, which integrate into specific
sites in their chromosomes [14–16]. These phages can be excised
by treatment with UV light, antibiotics, or by various stimuli in the
host [14,16–18]. The majority of EHEC strains associated with
HUS also harbor the eae gene encoding intimin [8,19], which
mediates intimate attachment of the bacteria to the intestinal
mucosa [20].
Although HUS is typically caused by EHEC, stx-negative/eae-
positive (stx2/eae+) E. coli strains are occasionally excreted by
patients with HUS [21,22]. However, the frequency of such strains
is unknown, and their origins and clinical significance are poorly
understood. To answer these questions, we studied stools from
HUS patients, processed so as to detect these variants. We
characterized the identified isolates and compared them to EHEC
associated with HUS with respect to serotypes, virulence and
fitness genes, phenotypes, and multilocus sequence types.
RESULTS
Frequency and serotypes of stx2/eae+ E. coli in
stools from patients with HUS
Between 1996 and 2006, stx2/eae+ E. coli strains were isolated
from stools of 43 (5.5%) of 787 individual, epidemiologically
unrelated HUS patients; additional 440 (55.9%) patients excreted
EHEC (Table 1), resulting in an overall isolation rate of 61.4%
(483 of 787). In none of the 483 culture-positive patients stx-
negative and EHEC strains were found together in the same stool.
Thirty-nine (90.7%) of the stx2/eae+ isolates belonged to serotypes
O26:H11/NM, O103:H2/NM, O145:H28/NM, and O157:H7/
NM (Table 1), which also accounted for the majority (91.1%) of
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belonged to serotype O121:H19 (which was also found among
EHEC; Table 1), and the remaining three were nontypeable
(Table 1). Each of the 43 stx2/eae+ strains lacked all known stx
alleles. The stools from which these strains were isolated contained
neither stx genes as demonstrated by PCR screening of enriched
primary stool cultures, nor free Stx as demonstrated by the Vero
cell assay on stool filtrates, nor any classic bacterial enteric
pathogens including Salmonella, Shigella, and Yersinia spp., and
Campylobacter jejuni.
Molecular characteristics of stx2/eae+ E. coli
isolates
We compared the stx2/eae+ E. coli O26:H11/NM, O103:H2/
NM, O121:H19, O145:H28/NM and O157:H7/NM isolated
from HUS patients to randomly selected HUS-associated EHEC
isolates of corresponding serotypes for the presence of several
genes that are known to be typically distributed in EHEC
[9,11,23–29] (Table 2). The stx2/eae+ strains of each serotype
closely resembled EHEC of the corresponding serotype with
respect to the presence or absence of putative non-stx virulence
genes encoding toxins (EHEC-hlyA, cdt-V), adhesins (iha, lpfAO26,
lpfAO157/OI 141, lpfAO157/OI 154, sfpA), and virulence determinants
of the O island 122 of E. coli O157:H7 (efa1, sen, pagC), as well as
the ter gene cluster and the irp2 and fyuA components of an iron
uptake system (Table 2). Moreover, the stx-negative and stx-
positive strains within each serotype shared the eae type and fliC
gene encoding the flagellin subunit of the H antigen (Table 2).
Consistently with the absence of stx, the chromosomal loci which
serve as integration sites for stx-converting bacteriophages in
EHEC O157:H7/NM (yehV, wrbA, yecE) [14,15] and EHEC
O26:H11/NM (wrbA, yecE) [16] were unoccupied in each of the
stx2/eae+ strains of the respective serotypes. This suggests that the
absence of stx in these strains was associated with the excision of
stx-harboring phages from their chromosomes.
Comparison of phenotypes of stx2/eae+ E. coli and
EHEC
The stx2/eae+ E. coli isolates shared with EHEC of the
corresponding serotypes several diagnostically useful phenotypes
(Table 3), but, in contrast to EHEC, their culture supernatants
were not toxic to Vero cells (Table 3), the cell line that is sensitive
to all Stx variants described until now. This suggests that these
strains did not produce Stx encoded by stx gene(s) that might have
been undetectable with our PCR protocol.
Multilocus sequence typing (MLST) analysis of stx2/
eae+ E. coli and EHEC
The phylogenetic relationships between the stx2/eae+ E. coli
O26:H11/NM, O103:H2/NM, O121:H19, O145:H28/NM, and
O157:H7/NM and EHEC of the same serotypes were determined
by MLST analysis of randomly selected strains (Figure 1). The stx-
negative and stx-positive strains of each serotype shared the same
sequence type or at least six of the seven alleles investigated [30]
and clustered therefore into the same clonal complex (Figure 1). In
contrast, the stx-negative strains of the five different serogroups
showed no close relationship based on their allelic profiles.
Serological investigations
Serum samples were collected during the acute phase of HUS
from 12 of 17 patients who shed stx2/eae+ E. coli O157 and from
10 of 26 patients who shed stx2/eae+ non-O157 strains. All 12
patients with E. coli O157 strains developed anti-O157 lipopoly-
saccharide (LPS) immunoglobulin M (IgM) antibodies. Among the
10 patients with non-O157 E. coli from whom serum samples were
available, only the patient who shed E. coli ONT:H7 developed
anti-O157 LPS IgM, suggesting a recent infection with E. coli
O157 which probably precipitated the HUS. IgM antibodies to
O157 LPS were not detected in the other nine sera from patients
who shed stx2/eae+ E. coli O26:H11/NM (n=5), O103:H2
(n=1), O145:H28/NM (n=2), and ONT:H6 (n=1). Each of the
five patients who excreted stx2/eae+ E. coli O26 had IgM
antibodies to O26 LPS; presence of anti-O103 and anti-O145
LPS antibodies in the one and two patients, respectively, who shed
stx2/eae+ E. coli strains of these serogroups could not be
determined because of insufficient amount of the serum
samples.
Characterization of HUS patients who excreted
stx2/eae+ E. coli but not other pathogens
Twenty of 43 HUS patients who shed stx2/eae+ E. coli as the only
pathogens were males and 23 were females. Thirty-seven patients
for whom information about age was available were children
between 5 months and 9 years (mean age, 31.3 months; median
age, 24 months). The mean age of these patients was significantly
lower than that of patients who shed EHEC strains (range, 4
months to 64 years, mean, 34.6 months; median, 27 months)
(P=0.003; Mann-Whitney U test). None of the 43 patients who
excreted stx2/eae+ E. coli strains and nine (2.0%) of the 440
patients who excreted EHEC died during the acute phase of HUS.
Table 1. Numbers of HUS patients from whom stx-negative/
eae-positive E. coli or EHEC strains were isolated and serotypes
of the isolates.
......................................................................
Serotype
a
Patients with stx2/eae+
isolates
Patients with EHEC
isolates
Number of
patients
Percentage
Total
Number of
patients
Percentage
Total
O26:H11/NM 13 30.2 58 13.2
O103:H2/NM 4 9.3 15 3.4
O111:H8/H10/NM 0 0 11 2.5
O145:H28/NM 5 11.6 31 7.0
O157:H7/NM (NSF) 2 4.7 221 50.2
O157:NM (SF) 15 34.9 76 17.3
Others 4
b 9.3 28
c 6.4
Total 43
d 100 440
d,e 100
aNM, nonmotile; NSF, non-sorbitol-fermenting; SF, sorbitol-fermenting.
bSerotypes (number of isolates, if more than one, in parenthesis): O121:H19,
ONT:H6 (2), ONT:H7; ONT, O antigen not typeable with antisera against E. coli
O antigens 1 to 181.
cSerotypes (number of isolates, if more than one, in parenthesis): O4:NM,
O55:H7, O55:HNT, O70:H8, O73:H18, O76:H19, O91:H21 (2), O98:NM, O104:H4,
O112:NM, O113:H21 (2), O119:H2, O121:H19 (2), O128:H2, O136:HNT, O145:H25
(2), O163:H19, O174:H21, Orough:H2, Orough:H11, Orough:NM, ONT:H21,
ONT:NM, ONT:HNT; Orough, autoagglutinable strains; HNT, H antigen not
typeable with antisera against E. coli H antigens 1 to 56.
dIn none of the 483 culture-positive patients stx-negative and stx-positive
(EHEC) strains were found in the same stool sample.
eFour patients shed two different EHEC serotypes including O157:H7 and
O145:NM; O157:H7 and O103:H2; SF O157:NM and O145:NM; O26:H11 and
O145:NM (the underlined serotypes which prevailed in the stools and were
isolated as the first are included in the table).
doi:10.1371/journal.pone.0001024.t001
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Stxs produced by EHEC are considered the major precipitants of
the microvascular endothelial injury that underlies HUS [1,12].
These toxins and their encoding genes are also the major targets
exploited in the laboratory diagnosis of EHEC infections [2,31].
Our finding of stx-negative E. coli strains that are closely related to
EHEC as the only putative bacterial pathogens in stools of ,5% of
patients with HUS during a long-term study sheds therefore new
light into microbiological, diagnostic, epidemiological, and clinical
aspects of this disorder.
Several lines of evidence support the hypothesis that these stx-
negative strains represent derivatives of original infecting EHEC
that lost the ability to express Stx (EHEC-LST), in these cases
because of stx-bacteriophage excision during infection. First, the
spectrum of serotypes of the stx-negative isolates is similar to that of
EHEC strains isolated from HUS patients (Table 1); in both cases,
serotype O157:H7/NM (including both non-sorbitol-fermenting
[NSF] and sorbitol-fermenting [SF] strains) is the most frequent,
being followed by serotypes O26:H11/NM, O145:H28/NM, and
O103:H2/NM (Table 1). These serotypes are generally not
excreted by healthy subjects [32; H. Karch, unpublished data].
The absence of serogroup O111, which was found in 2.5% of
EHEC-excreting patients, among the HUS-associated EHEC-
LST isolates (Table 1) is probably because stx1, which is the most
prevalent stx in EHEC O111 [33] is encoded within a defective
prophage, which has been immobilized in the EHEC genome
[34], preventing the stx loss by phage excision. Also, the ratio
between SF and NSF EHEC-LST O157 isolates (88% vs. 12%)
(Table 1), while in contrast to that observed between SF and NSF
EHEC O157 isolated from HUS (26% vs. 74%) (Table 1), is
proportional to the greater frequency with which the stx loss occurs
in SF EHEC O157:NM [21,22]. Second, the EHEC-LST isolates
share with EHEC of the corresponding serotypes non-stx virulence
and fitness genes and belong to the same MLST clonal complexes.
This demonstrates a common phylogeny and conservation of
variable genome regions in the two groups of organisms. Third,
the possibility of stx loss from EHEC O26:H11/NM and SF
EHEC O157:NM during the course of HUS has been proposed in
our previous study based on closely related molecular character-
istics of stx-positive and stx-negative isolates from the initial and
follow-up stools, respectively [21]; the stx loss has been confirmed
in vitro [16]. Fourth, the genomic loci where stx-converting
bacteriophages integrate into the genomes of EHEC O26:H11/
NM [16] and O157:H7/NM [14,15] were unoccupied in all stx2/
eae+ isolates of these serotypes indicating that the stx loss resulted
from the excision of stx-converting phages. Altogether, these data
strongly suggest that the stx2/eae+ E. coli strains isolated from
HUS patients were EHEC-LST.
Although the design of the study does not allow to determine
whether the stx2/eae+ E. coli strains could be primary pathogens
that triggered the HUS in patients from whom they were isolated,
this seems to be unlikely, taking into account the paradigm that
HUS is caused by Stx [1,2]. However, because they have
unoccupied stx-bacteriophage integration sites, the stx2/eae+ E.
coli O26:H11/NM and O157:H7/NM strains can be transduced
with stx-harboring phages and converted thus to EHEC, at least in
vitro [16]. Whether such an event can occur during infection and
whether it could trigger HUS remains to be established.
Moreover, conditions favoring lysogenic conversion or stx loss in
vivo are poorly understood [18].
The ratio between EHEC-LST (5.5%) and EHEC (55.9%)
isolated in our study is ,1:10. The finding that every 10
th patient
with HUS, a condition that was most probably triggered by an
EHEC infection, does not shed EHEC, but rather excretes EHEC-
LST when stool is subjected to appropriate microbiological
analysis, has important practical implications. First, the stx loss
in an EHEC strain during infection can mislead epidemiological
investigations because an stx-negative strain would not be, based
on currently used criteria, considered to be epidemiologically
related to stx-positive strains, even though of the same serotype.
Therefore, the awareness of the possibility that a patient with HUS
can excrete, in lieu of the original infecting EHEC, EHEC-LST
which shares non-stx molecular characteristics with EHEC of the
corresponding serotype, can assist epidemiologists to link correctly
epidemiologically related cases, to identify the source of the
infection and to trace modes of transmission. In such studies it is
necessary to bear in mind that the loss of stx-harboring
bacteriophages can alter pulsed-field gel electrophoresis patterns
of the strains [15,16], so that the epidemiologically related stx-
positive and stx-negative strains can more or less differ in their
fingerprints [16].
Table 3. Comparison of phenotypes of stx-negative and stx-positive E. coli strains of serotypes O26:H11/NM, O103:H2/NM,
O121:H19, O145:H28/NM, and O157:H7/NM.
..................................................................................................................................................
Phenotype
a Occurrence of the phenotype among stx-negative and stx-positive E. coli strains of serotype
b
O26:H11/NM O103:H2/NM O121:H19 O145:H28/NM O157:H7/NM O157:NM
stx2 stx+ stx2 stx+ stx2 stx+ stx2 stx+ stx2 stx+ stx2 stx+
(n=13) (n=15) (n=4) (n=8) (n=1) (n=2) (n=5) (n=10) (n=2) (n=10) (n=15) (n=20)
Sorbitol fermentation ++++++++22++
Rhamnose fermentation 22+++++++ (50) + (60) 22
Tellurite resistance + (92) + (93) + (25) + (13) ++++++22
EHEC hemolysin ++++++++++22
Cytolethal distending toxin
V (CDT-V)
2222222222+ (87)
c + (85)
c
Shiga toxin 2 + 2 + 2 + 2 + 2 + 2 +
aThe phenotypes were determined as described in Materials and Methods.
bNM, nonmotile; stx2, stx-negative; stx+, stx-positive. n, number of strains tested; +, all strains tested (n) expressed the phenotype; 2, none of the strains tested (n)
expressed the phenotype; if a subset of the strains expressed the phenotype, the percentage is given in parenthesis.
cThe CDT-V titers were 1:4–1:16 in both stx-negative and stx-positive strains as determined by Chinese hamster ovary cell assay [26].
doi:10.1371/journal.pone.0001024.t003
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1024Figure 1. Phylogenetic relatedness of stx-negative and stx-positive E. coli strains within serotypes O26:H11/NM, O103:H2/NM, O121:H19,
O145:H28/NM, and O157:H7/NM. Unrooted neighbor-joining tree was generated from allelic profiles of seven housekeeping genes (adk, fumC, gyrB,
icd, mdh, purA, recA) [30] using the Phylip software package (http://evolution.genetics.washington.edu/phylip.html). ST, sequence type; CC, clonal
complex (at least six identical alleles); NM, non-motile; stx, Shiga toxin-encoding gene; stx2, stx-negative; stx+, stx-positive; SF, sorbitol-fermenting;
NSF, non-sorbitol-fermenting. Strains of serotype O121:H19 differ by at least 4 alleles from all known sequence types and have therefore no assigned
clonal complex. Scale bar, 5% estimated evolutionary distance.
doi:10.1371/journal.pone.0001024.g001
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PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1024Second, microbiological identification of patients infected with
EHEC O157:H7 early in illness is strongly associated with a good
nephrologic outcome [1], probably because such an expeditious
diagnosis prompts early volume expansion [35]. In patients
excreting an EHEC-LST, the microbiological diagnosis may be
delayed or the EHEC etiology of the disease is missed using tests
that rely solely on the detection of stx genes or Stx production
[31]. However, this concern might or might not be appropriate,
depending on when in the course of the disease EHEC-LST
replace the EHEC that almost certainly preceded the EHEC-
LST. Whereas underdiagnosing EHEC-LST might not be
clinically critical in patients with overt HUS who had already
developed microvascular injury, the information about the
presence of EHEC-LST in the stool (which may indicate
continuing presence of the original EHEC in an amount
undetectable by PCR stx screening) is of an important diagnostic
value in patients with diarrhea, especially those with bloody
diarrhea which often precedes HUS [1,2,5]. In such patients,
a prompt diagnosis of EHEC-LST infection should alert the
treating physician that the patient could develop HUS and should
be monitored assiduously, receive isotonic volume expansion
[35], and not be given antibiotics [36,37] or antimotility agents
[1,38]. Clearly, we need better, and broader, microbiologic
procedures to detect, in addition to stx or Stx, also non-stx/Stx
EHEC targets.
How should EHEC-LST be detected? eae, which is present in
the majority of EHEC isolated from HUS patients in Europe
[2,19] and the United States [7,8], appears to be a quite
appropriate additional diagnostic target. Specifically, based on
our finding that eae-negative EHEC account for ,4% of HUS-
associated EHEC isolates in Germany [19] and assuming, based
on the data from the present study, that stx loss occurs in ,10% of
the infecting EHEC, the using eae as a target to identify EHEC-
LST would miss only ,0.4% of such strains. This proportion of
missed pathogens might be higher in regions where eae-negative
EHEC account for a higher proportion of HUS isolates [10,39]. In
this case, the gene encoding the Stx-producing E. coli autoagglu-
tinating adhesin (saa) [39], which is present in the majority of eae-
negative EHEC associated with HUS [39], might be a suitable
alternative to search for EHEC-LST. Optimal detection algo-
rithms, and non-stx loci, depend on geographic and temporal-
specific epidemiological trends, and for this reason it is necessary
to continue microbiological surveillance. In this regard, it is critical
to not abandon culture in favor of non-culture methodology, but
to apply both modalities simultaneously to all stool specimens. In
consideration of current epidemiology and etiology [1,2], we
believe that optimal diagnosis for both EHEC and EHEC-LST
should consist of plating on sorbitol MacConkey (SMAC) agar
(detection of NSF E. coli O157:H7/NM) and enterohemolysin
agar (detection of the most frequent non-O157 serotypes based on
the enterohemolytic phenotype) (Table 3) [9,24], Stx or stx gene
testing, and targeting eae (or saa) and sfpA (the latter for a specific
detection of SF E. coli O157:NM) (Table 2) [23]. In culture-
negative patients for whom serum samples are available, detection
of antibodies against LPSs of the most frequent E. coli serogroups
associated with HUS (both O157 and non-O157) can be an
alternative approach to detect infection with both EHEC and
EHEC-LST.
The application of stx/Stx-independent diagnostic strategies to
identify EHEC-LST in HUS patients appears to be appropriate to
consider for several reasons. First, stool samples from such patients
are frequently collected only after HUS develops, i.e. $1 week
after the onset of the prodromal diarrhea [1], as was true also for
the majority of patients in our study. At this point in illness, EHEC
might have been cleared [40] or stx might have been lost from
infecting organisms [21]. In the latter case, using a non-stx
diagnostic target such as eae or saa can still identify, with a high
probability, the causative agent. Moreover, such diagnostic
approaches would permit a prospective systematic clinical study
to determine if stx loss by the infecting EHEC during the course of
HUS might result in a less severe acute disease and/or a decreased
rate of late sequelae.
Our study has two major limitations. First, although we
systematically sought stx2/eae+ E. coli strains in stools that were
negative for EHEC, as indicated by negative result of PCR
screening for stx genes, we did not seek such strains in stool
samples that contained EHEC. Stools that were stx-positive in
PCR screening were only analyzed for stx-positive colonies. This
approach rendered it impossible to determine if some of the
patients had both stx2/eae+ E. coli strains and EHEC in the same
stool, a situation that would indicate progressive loss of stx by the
infecting EHEC population. Although poly-isolate analyses in
other studies where a panel of markers were used including stx
nucleic acid hybridization did not detect such a mixed population
[41,42], in these studies, stools were collected early in illness, and
only five colonies were studied. Further studies targeting
systematically both stx and eae (or other loci) in sequential stools
from HUS patients are needed to determine the dynamic of stx loss
during infection and to identify factors that could influence this
process, such as serotype of the infecting EHEC, patient-related
and/or environmental factors. Second, we do not have sufficient
data to determine if antibiotics played a role in stx loss, as
suggested in several experimental studies [14,17].
In conclusion, at the time of microbiological analysis, an
appreciable subset of patients with HUS shed no longer EHEC
sensu stricto, but do excrete EHEC that lost stx. Diagnostic
strategies need to be formulated to detect such pathogens and
treating physicians should be immediately informed. Patients who
shed such strains should be considered as potentially infected by
EHEC and managed accordingly, at least until more data about
the clinical significance of the EHEC-LST emerge. While not
changing the paradigm that Stxs are the critical virulence
determinant of EHEC responsible for HUS, our data do
demonstrate the necessity of taking into account possible genetic
changes of the pathogens during infection when developing
appropriate diagnostic strategies and interpreting results of
microbiological analyses.
MATERIALS AND METHODS
Patients
During routine diagnostic work between 1996 and 2006, we
sought stx2/eae+ E. coli and EHEC strains in stools (one stool per
patient) from 787 epidemiologically unrelated patients with HUS.
The patients were hospitalized in 23 pediatric nephrology centers
in Germany and Austria described previously [5], with an
extended period for patient enrollment until December 2006.
Stools from patients who excreted stx2/eae+ E. coli strains and
EHEC strains were collected between 5 and 14 days (median 9
days) and between 5 and 13 days (median 8 days), respectively,
after the onset of prodromal diarrhea. The difference in the time of
stool collection was not significant (P=0.24, Mann-Whitney U
test). HUS was defined as microangiopathic hemolytic anemia
(hematocrit ,30%, with evidence of the destruction of erythro-
cytes on a peripheral-blood smear), thrombocytopenia (platelet
count ,150,000/mm
3), and renal insufficiency (serum creatinine
concentration greater than the upper limit of the normal range for
age) [36].
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stx2/eae+ E. coli strains were sought in parallel with EHEC as
described [21,23]. Briefly, stool samples enriched in Hajna broth
were specifically enriched for E. coli O157 using immunomagnetic
separation with Dynabeads anti-E. coli O157 (Invitrogen, http://
www.invitrogen.com) and magnetically separated organisms were
cultured on SMAC agar and cefixime-tellurite (CT)-SMAC agar
(Oxoid, http://www.oxoid.com). To identify non-O157 E. coli
strains, non-separated broth cultures were inoculated onto SMAC
and enterohemolysin agar (Sifin, http://www.sifin.de). The over-
night growth was harvested into saline and screened by PCR for
stx1, stx2, eae, rfbO157 and sfpA genes [21,23]; the latter two PCRs
specifically detect E. coli O157 [23]. stx-positive stool cultures were
further processed to isolate EHEC strains [21,23]. From cultures
which were stx-negative but eae-positive the eae-positive strains were
isolated using colony blot hybridization with digoxigenin-labeled
eae probe [21]. Among the 43 stx2/eae+ strains described here, 27
were isolated in this study and 16 (12 O157:H7/NM and four
non-O157) in our previous studies [21,22].
Phenotypic methods
Resulting isolates were biochemically confirmed as E. coli (API 20
E; bioMe ´rieux, http://www.biomerieux.de) and serotyped [43].
Fermentations of sorbitol and rhamnose were detected on SMAC
and rhamnose MacConkey agar (Sifin), respectively [24]. The
enterohemolytic phenotype was sought on enterohemolysin agar
and resistance to tellurite on CT-SMAC [25]. Stx activity in
culture supernatants and stool filtrates was detected using the Vero
cell assay [19]. Production of cytolethal distending toxin (CDT)
was determined using Chinese hamster ovary cells [26].
Genotypic characterization
eae, presently known stx alleles [2], and other toxin (EHEC-hlyA,
cdt-V) and adhesin (iha, lpfAO26, lpfAO157/OI 141, lpfAO157/OI 154,
sfpA) genes were detected using established PCR protocols
[19,23,24,26,27,33,44]. Moreover, the isolates were PCR tested
for putative virulence genes located within O island 122 of EHEC
O157:H7 strain EDL933 (efa1, sen, pagC) [11,28], the ter gene
cluster encoding tellurite resistance [25], and irp2 and fyuA, which
are components of the iron uptake system encoded on the high
pathogenicity island [29]. eae genes were subtyped [45] and
genotypes of the flagellin-encoding fliC gene were determined
[9,33]. The intact or occupied status of chromosomal loci that
serve as phage integration sites (yehV, wrbA, yecE) was investigated
using PCR primers and conditions described previously [14–16].
MLST
MLST was performed by analyzing internal fragments of seven
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, recA) [16,30].
The alleles and sequence types were assigned in accordance with
the E. coli MLST website (http://web.mpiib-berlin.mpg.de/mlst/
dbs/Ecoli). The genetic relationships between different sequence
types were determined using eBURST [46] and a phylogenetic
tree based on neighbor-joining analysis was constructed using the
Phylip package (http://evolution.genetics.washington.edu/phylip.
html).
Detection of additional classic bacterial enteric
pathogens
Salmonella, Shigella, and Yersinia spp., and Campylobacter jejuni were
sought using standard procedures [47–49].
Serological investigation
IgM antibodies against the O157 and O26 LPS antigens were
sought in sera from acute phase of HUS using an immunoblot
[21].
Statistical analysis
The non-parametric Mann-Whitney U (Wilcoxon) two-sample test
for independent sample groups and OpenStat2 Software (http://
www.statpages.org/miller/openstat/) were used for statistical
analysis. P values ,0.05 were considered significant.
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